Products

TGV-inhalonix is focused on the development of novel, nebulized medicine to treat infections that cause significant decline in life-expectancy in Cystic Fibrosis patients. We have made life-changing breakthrough discoveries that can increase the lifespan of patients with cystic fibrosis and help to fight today’s incurable resistant respiratory diseases among this patient population. It is our responsibility to accelerate way from our innovation to medicines thus new therapeutics not be late and be on time enhancing and extending patients’ lives.

Mul-1867

Mul-1867 is the first inhaled antimicrobial being developed against multidrug-resistant bacteria and fungi. Initial testing indicates Mul-1867 to be a significant breakthrough in the war on lung infections in patients with cystic fibrosis.

Read more about Mul-1867

Mul-1867